Trial Profile
An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites Following a Single-dose Oral Administration
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 May 2016
Price :
$35
*
At a glance
- Drugs Nebicapone (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Bial
- 20 May 2016 New trial record